50% recruitment milestone reached for COBRA prostate cancer trial in the US
Sydney, Australia 27 October 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT052491271) for patients with prostate cancer has reached the fifty percent recruitment milestone, with 25 out…